Redefining care for people with blood disorders
Galecto is a clinical-stage biopharmaceutical company developing small-molecule and antibody therapeutics targeting galectin proteins for the treatment of fibrosis, cancer, and hematologic disorders. Its pipeline includes programs for idiopathic pulmonary fibrosis and myeloproliferative neoplasms. In March 2026 the company announced a name change to Damora Therapeutics following its acquisition of Damora Therapeutics and a strategic pivot to mutant calreticulin-driven blood disorders.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2025
Sep 2020
Oct 2018
Jan 2010
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
